[30 September 2019] The IBTA’s monthly e-News has now been released and been emailed to all subscribers. Some of the highlights from this month include news that researchers conducting the phase 3 CeTeG/NOA-09 study saw significantly longer overall survival for those patients who received lomustine-temozolomide therapy compared to those on standard temozolomide alone.
[03 September 2019] A brief overview of IBTA’s Vision, Mission and Purpose, and how we achieve these through our national and international collaborative work.
[27 July 2019] The Sub-Saharan Africa Neuro-oncology Collaborative (S-SANOC) planning meeting which took place at the Tower Hotel, London, United Kingdom in October 2017 formed the foundation for the birth of the Society for Neuro-Oncology Sub-Saharan Africa (SNOSSA).
[24 July 2019]All.Can conducted a patient survey in over 10 countries, which asked almost 4,000 cancer patients and caregivers where they identified inefficiencies in their care.
[24 July 2019] The international All.Can cancer initiative has today (24 July 2019) published a major report urging health officials, governments and decision-makers to ‘do the right thing by patients’
[27 May 2019] NCI-CONNECT has established a national network of centers willing and eager to participate in studying rare brain and spine tumours…
Like us on Facebook and follow us on Twitter.
The IBTA is a not-for-profit, limited liability company incorporated in England and Wales, Company Number: 6031485. © copyright 2017 - 2019 The International Brain Tumour Alliance [IBTA]. All Rights Reserved. Design by Feelingpeaky
Sitemap | Company information | Disclaimer | Privacy Policy | Cookies Website Photo Credits
This content is blocked. Accept cookies to view the content.
The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.
